NSE · PFIZER
Pfizer Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2,708 Cr with net profit ₹722 Cr — a 26.68% net margin, versus 31.28% the period before.
Shareholding
As of 2026-06-30
- Promoter63.92%
- Public16.63%
- FII1.65%
- DII17.8%
1,02,478 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.35× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Multinational · ranked #2 of 6 by market cap · medians across 5 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd. | ₹44,493 Cr | 160.15 | 19.62 | 45.69% | 27.11% |
| Pfizer Ltd.(this company) | ₹21,754 Cr | 108.86 | 5.18 | 17.19% | 28.61% |
| Sanofi Consumer Healthcare India Ltd. | ₹10,929 Cr | 161.19 | 31.14 | 76.46% | 28.01% |
| Sanofi India Limited | ₹7,876 Cr | 76.77 | 9.43 | 42.11% | 20.53% |
| Novartis India Ltd. | ₹3,950 Cr | 156.4 | 4.82 | 11.39% | 26.38% |
| Abbott India Limited | ₹464 Cr | 149.29 | 12.35 | 37.86% | 13.6% |
AI analysis
AI-generated · google/gemini-2.5-flashPfizer Ltd. is listed on the Indian markets with a market capitalization of Rs 20943 Cr. The company reported revenue of Rs 2707.6 Cr and a profit margin of 28.67%.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +Return on Capital Employed (ROCE) is 21.06%, and Return on Equity (ROE) is 17.19%.
- +The promoter holding of 63.9224% has remained consistent since September 2016.
- +The reported profit margin is 28.67%.
Negatives
- −The net profit declined to Rs 722.43 Cr in March 2026 from Rs 767.6 Cr in March 2025.
- −Earnings per share decreased to Rs 157.92 in March 2026 from Rs 167.79 in March 2025.
- −Foreign Institutional Investor (FII) holding decreased from 3.2377% in June 2018 to 1.6503% in June 2026.
Financial Performance
Pfizer Ltd. reported annual revenue of Rs 2707.6 Cr in March 2026. This represents an increase from Rs 2453.6 Cr in March 2025. Net profit for March 2026 was Rs 722.43 Cr, down from Rs 767.6 Cr in March 2025. The company's highest annual net profit was Rs 767.6 Cr in March 2025.
Profitability & Returns
The company's profit margin stood at 28.67%. Return on Equity (ROE) was 17.19% and Return on Capital Employed (ROCE) was 21.06%. Earnings per share (EPS) for March 2026 were Rs 157.92. The annual EPS in March 2025 was Rs 167.79.
Balance Sheet
Pfizer Ltd. has a debt-to-equity ratio of 0, indicating no debt. The book value per share is Rs 918.71. The company has a dividend yield of 164%.
Ownership & Pledges
As of June 30, 2026, promoters held 63.9224% of the company's shares. Domestic Institutional Investors (DII) held 17.7985% and Foreign Institutional Investors (FII) held 1.6503%. Public shareholding was 16.6288%. There were no promoter share pledges reported.
Regulatory & Surveillance
No information regarding regulatory surveillance measures for Pfizer Ltd. was provided in the available data. The company has no outstanding promoter pledges.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.